Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Standard Lithium Ltd (SLI) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Standard Lithium LtdTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Standard Lithium Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.03B), while Standard Lithium Ltd trades at $2.45 (market cap $624.94M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 46.5× Standard Lithium Ltd's market cap. Which is the better fit depends on your goals.

ALNYSLI
Market Cap
$29.03B$624.94M
Sector
HealthBasic Materials
52-Week High
$491.22$5.65
52-Week Low
$205.48$1.93
Enterprise Value
$26.99B$484.14M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $219.20, down 1.43% amid bearish technical signals and recent earnings volatility. The stock faces near-term pressure from a Q2 2026 EPS miss and lowered 2026 sales guidance, but maintains strong fundamentals with 2025 revenue of $3.71B and net income of $313.75M. Analyst consensus remains bullish with a $370.07 price target, though multiple law firms are investigating potential securities fraud as reported by PRNewsWire and GlobeNewsWire in early August 2026.

Outlook is mixed: robust revenue growth and high profitability margins support long-term potential, but legal uncertainties and recent earnings disappointments pose significant risks. The stock's current valuation (P/E 38.19) reflects growth expectations, yet investor caution is warranted given technical bearishness and ongoing investigations.

Standard Lithium Ltd

Standard Lithium (SLI) trades at $2.37, up 4.41% with a bullish technical signal despite mixed earnings performance. The company maintains 100% analyst buy ratings and strong institutional interest, including Amundi's 64.9% stake increase. Recent developments show progress toward final investment decision for the South West Arkansas lithium project, supported by a $225M DOE grant and key construction contracts. Financials reflect development-stage challenges with negative profitability metrics but substantial financing activity.

Outlook remains constructive as SLI transitions toward production with major project de-risking, though execution risks and negative cash flows warrant monitoring. The stock presents growth potential in lithium sector expansion but faces operational and funding challenges during development phase. Current valuation at 1.72x book value reflects market optimism about project economics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Standard Lithium Ltd

Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.

Read more on SLI